Back to Journals » Journal of Hepatocellular Carcinoma » Volume 8

Targeting De Novo Lipogenesis and Cholesterol Biosynthesis Simultaneously is a Novel Therapeutic Option for Hepatocellular Carcinoma

Authors Liu Q, Dong X

Received 24 August 2020

Accepted for publication 13 January 2021

Published 28 January 2021 Volume 2021:8 Pages 19—21

DOI https://doi.org/10.2147/JHC.S278517

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Dr Ahmed Kaseb


Qian Liu,1 Xifeng Dong2

1Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300020, People’s Republic of China; 2Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300020, People’s Republic of China

Correspondence: Xifeng Dong
Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300020, People’s Republic of China
Email dongxifeng@sdu.edu.cn

Abstract: Hepatocellular carcinoma (HCC) is one of the most common and serious types of cancer in the world. Currently, the treatment options for patients with HCC are limited. Lipid metabolic alterations are being recognized as a therapeutic target in the past few years. De novo lipogenesis has been frequently observed in HCC. Fatty acid synthase (FASN) is the key enzyme of de novo lipogenesis. Previous studies have indicated that loss of FASN suppresses the growth of HCC cells, but it cannot completely prevent HCC formation in vivo. Thus, other mechanisms that can support HCC tumor formation in the absence of de novo lipogenesis maybe existed. In a study recently published in Gut, Che and colleague investigated the functions of Fasn in HCC mouse model and explore the crosstalk between de novo lipogenesis and cholesterol biosynthesis-associated pathway during HCC development. These findings highlight the simultaneous inhibition of de novo lipogenesis and cholesterol biosynthesis as a novel therapeutic and prevention strategy for HCC.

Keywords: hepatocellular carcinoma, HCC, cholesterol, fatty acid, lipogenesis, biosynthesis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]